Equities researchers at HC Wainwright boosted their Q1 2025 earnings estimates for shares of ADC Therapeutics in a note ...

Q4 2024 Earnings Call Transcript March 27, 2025 ADC Therapeutics SA beats earnings expectations. Reported EPS is $-0.29, ...

ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $1.03 per share a year ago.

In a report released on April 3, Gregory Renza from RBC Capital maintained a Buy rating on ADC Therapeutics (ADCT – Research Report), with a ...

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to ...

ADC Therapeutics (NYSE:ADCT – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright ...

Guggenheim lowered the firm’s price target on ADC Therapeutics (ADCT) to $7 from $10 and keeps a Buy rating on the shares. Q4 results were ...

ADC THERAPEUTICS SA -REDH ($ADCT) posted quarterly earnings results on Thursday, March 27th. The company reported earnings of -$0.29 per share, beating estimates of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...